Neuroblastoma Screening at 1 Year of Age: The Final Results of a Controlled Trial.
Frank BertholdClaudia SpixRudolf ErttmannBarbara HeroJoerg MichaelisJoern TreunerAngela ErnstFreimut H SchillingPublished in: JNCI cancer spectrum (2021)
Neuroblastoma screening at 1 year of age reduced neither stage 4 incidence nor neuroblastoma mortality and was affected by overdiagnosis, leading to unnecessary treatment. A few screening-detected stage 4 cases represent a biologically interesting subgroup but do not change the recommendation to close the "catecholamine-based neuroblastoma screening book."